Abbott Korea launches film-type hepatitis B treatment for the first time
Today, Abbott Korea(CEO Yoo-seok Jung) launched ‘Filclude ODF(generic name: entecavir),’ the first film-type hepatitis B treatment, in respective 0.5mg and 1mg.
‘Filclude ODF,’ a film-type drug which innovatively improved the existing hepatitis B treatment, entecavir,’ can be administered by mel...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
